IN8bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
47.9%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$1.09next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly21.9MTarget: Sufficient capital to fund operations through April 2027
Median Progression-Free Survival (mPFS) for DeltEx DRI in GBM Annually13.0Target: Significant improvement over standard-of-care (6.6 months)
INB-100 Expansion Cohort Enrollment Quarterly25.0Target: Complete target enrollment of approximately 25 patients
Watch Items
- Going Concern Status and Cash RunwayTrigger: Cash reserves falling below $10 million without additional financingAction: Accelerate strategic partnerships, execute milestone-based private placements, or implement further cost-saving measures.
- FDA Regulatory Pathway Engagement for Glioblastoma (GBM)Trigger: Feedback from FDA on registrational pathways for INB-200/INB-400Action: Align clinical trial designs with FDA guidance and prepare protocol submissions for registrational studies.
- Preclinical Data Readouts for γδ TCE Platform (INB-600/INB-619)Trigger: Initial animal data and IND-enabling study results in 2026Action: Evaluate therapeutic efficacy and safety profiles to support IND applications for autoimmune and oncology indications.
Research as of 20 Jun 2026